Literature DB >> 15523642

Disruption of exonic splicing enhancer elements is the principal cause of exon skipping associated with seven nonsense or missense alleles of NF1.

Andrea Zatkova1, Ludwine Messiaen, Ina Vandenbroucke, Rotraud Wieser, Christa Fonatsch, Adrian R Krainer, Katharina Wimmer.   

Abstract

Nonsense, missense, and even silent mutation-associated exon skipping is recognized in an increasing number of genes as a novel form of splicing mutation. The analysis of individual mutations of this kind can shed light on basic pre-mRNA splicing mechanisms. Using cDNA-based mutation detection analysis, we have identified one missense and six nonsense mutations that lead to different extents of exon-lacking transcripts in neurofibromatosis type 1 (NF1) patients. We confirmed mutation-associated exon skipping in a heterologous hybrid minigene context. There is evidence that the disruption of functional exonic splicing enhancer (ESE) sequences is frequently the mechanism underlying mutation-associated exon skipping. Therefore, we examined the wild-type and mutant NF1 sequences with two available ESE-prediction programs. Either or both programs predicted the disruption of ESE motifs in six out of the seven analyzed mutations. To ascertain the function of the predicted ESEs, we quantitatively measured their ability to rescue splicing of an enhancer-dependent exon, and found that all seven mutant ESEs had reduced splicing enhancement activity compared to the wild-type sequences. Our results suggest that the wild-type sequences function as ESE elements, whose disruption is responsible for the mutation-associated exon skipping observed in the NF1 patients. Further, this study illustrates the utility of ESE-prediction programs for delineating candidate sequences that may serve as ESE elements. However, until more refined prediction algorithms have been developed, experimental data, preferably from patient tissues, remain indispensable to assess the clinical significance, particularly of missense and silent mutations, and to understand the structure-function relationship in the corresponding protein. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15523642     DOI: 10.1002/humu.20103

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  37 in total

1.  Molecular diagnosis of neurofibromatosis type 1: 2 years experience.

Authors:  Siân Griffiths; Peter Thompson; Ian Frayling; Meena Upadhyaya
Journal:  Fam Cancer       Date:  2007       Impact factor: 2.375

2.  Splicing analysis disclosed a determinant single nucleotide for exon skipping caused by a novel intraexonic four-nucleotide deletion in the dystrophin gene.

Authors:  Van Khanh Tran; Yasuhiro Takeshima; Zhujun Zhang; Mariko Yagi; Atsushi Nishiyama; Yasuaki Habara; Masafumi Matsuo
Journal:  J Med Genet       Date:  2006-05-31       Impact factor: 6.318

3.  Loss of exon identity is a common mechanism of human inherited disease.

Authors:  Timothy Sterne-Weiler; Jonathan Howard; Matthew Mort; David N Cooper; Jeremy R Sanford
Journal:  Genome Res       Date:  2011-07-12       Impact factor: 9.043

4.  Sex-dependent association of a common low-density lipoprotein receptor polymorphism with RNA splicing efficiency in the brain and Alzheimer's disease.

Authors:  Fanggeng Zou; Rangaraj K Gopalraj; Johann Lok; Haiyan Zhu; I-Fang Ling; James F Simpson; H Michael Tucker; Jeremiah F Kelly; Samuel G Younkin; Dennis W Dickson; Ronald C Petersen; Neill R Graff-Radford; David A Bennett; Julia E Crook; Steven G Younkin; Steven Estus
Journal:  Hum Mol Genet       Date:  2007-12-08       Impact factor: 6.150

5.  Seemingly neutral polymorphic variants may confer immunity to splicing-inactivating mutations: a synonymous SNP in exon 5 of MCAD protects from deleterious mutations in a flanking exonic splicing enhancer.

Authors:  Karsten Bork Nielsen; Suzette Sørensen; Luca Cartegni; Thomas Juhl Corydon; Thomas Koed Doktor; Lisbeth Dahl Schroeder; Line Sinnathamby Reinert; Orly Elpeleg; Adrian R Krainer; Niels Gregersen; Jørgen Kjems; Brage Storstein Andresen
Journal:  Am J Hum Genet       Date:  2007-01-18       Impact factor: 11.025

6.  Knockin mouse model of the human CFL2 p.A35T mutation results in a unique splicing defect and severe myopathy phenotype.

Authors:  Samantha M Rosen; Mugdha Joshi; Talia Hitt; Alan H Beggs; Pankaj B Agrawal
Journal:  Hum Mol Genet       Date:  2020-07-29       Impact factor: 6.150

7.  Prediction and assessment of splicing alterations: implications for clinical testing.

Authors:  Amanda B Spurdle; Fergus J Couch; Frans B L Hogervorst; Paolo Radice; Olga M Sinilnikova
Journal:  Hum Mutat       Date:  2008-11       Impact factor: 4.878

8.  Effect of BRCA2 sequence variants predicted to disrupt exonic splice enhancers on BRCA2 transcripts.

Authors:  Phillip J Whiley; Christopher A Pettigrew; Brooke L Brewster; Logan C Walker; Amanda B Spurdle; Melissa A Brown
Journal:  BMC Med Genet       Date:  2010-05-28       Impact factor: 2.103

9.  Genomic features defining exonic variants that modulate splicing.

Authors:  Adam Woolfe; James C Mullikin; Laura Elnitski
Journal:  Genome Biol       Date:  2010-02-16       Impact factor: 13.583

10.  Neurofibromin 1 (NF1) defects are common in human ovarian serous carcinomas and co-occur with TP53 mutations.

Authors:  Navneet Sangha; Rong Wu; Rork Kuick; Scott Powers; David Mu; Diane Fiander; Kit Yuen; Hidetaka Katabuchi; Hironori Tashiro; Eric R Fearon; Kathleen R Cho
Journal:  Neoplasia       Date:  2008-12       Impact factor: 5.715

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.